Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.ai Announces First New Customer Win For its AI Powered Photography Studio (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > M101 in the PR
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(106)
•••
Comment by G1945Von Mar 11, 2023 7:21am
103 Views
Post# 35332287

RE:M101 in the PR

RE:M101 in the PR
FarmerBetty wrote: Nothing to do with a win from my previous post just more obvious misleading and suppressing information. Look how they snuck there PD info coming reported repeatedly last year to be in the second half of last year into the sec filing just released. They wouldn't want to PR there IND toxicology reports etc, like other have in filing for IND's?  Think about it, first bullet, "Completed all preclinical studies and manufacturing to support PMN 310 submission to US food and drug admininstration". So why has it not been submitted? Get on board on stop defending them let the SEC know what these guys are all about!

At the end of 2022 they still have 6 FTE employees and 1 part time as per sec filing. TheBOD of directors did do some important work in November in approving an annual incentive plan (Bonus Plan) for employees. 




Farmer Betty, why don't you wait to see what happens in the next 60 days and then you can tell us I told you so if the IND fails to materialize?

You seem to get a lot of pleasure from your habitual smearing of the company.


G1945V
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities